INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 211 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $318 | -100.0% | 5,020 | -72.0% | 0.04% | -65.5% |
| Q2 2022 | $1,022,000 | +41.4% | 17,910 | +51.5% | 0.12% | +36.5% |
| Q1 2022 | $723,000 | -11.0% | 11,820 | -45.7% | 0.08% | -12.4% |
| Q3 2021 | $812,000 | +822.7% | 21,780 | +85.9% | 0.10% | +546.7% |
| Q3 2019 | $88,000 | -58.7% | 11,716 | -2.8% | 0.02% | -53.1% |
| Q2 2018 | $213,000 | -11.2% | 12,048 | +5.6% | 0.03% | -11.1% |
| Q1 2018 | $240,000 | -7.3% | 11,408 | -36.3% | 0.04% | -21.7% |
| Q4 2017 | $259,000 | +6.1% | 17,909 | +15.9% | 0.05% | +15.0% |
| Q3 2017 | $244,000 | +2.1% | 15,446 | -2.5% | 0.04% | -37.5% |
| Q4 2016 | $239,000 | – | 15,847 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |